SCHEMBL4403245

SCHEMBL4403245

NC(=O)c1cnc(Cl)cc1Nc1ccc(C2CCOCC2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 12/20 0.52
SERPINE1 P05121 1/20 0.42
JAK2 O60674 4/20 0.41
JAK1 P23458 4/20 0.41
JAK3 P52333 2/20 0.41
KCNH2 Q12809 2/20 0.41
TYK2 P29597 1/20 0.41
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
LCK P06239 1/20 0.39
LYN P07948 1/20 0.39
MAPK3 P27361 1/20 0.39
MAPK1 P28482 1/20 0.39
ZAP70 P43403 1/20 0.39
TYRO3 Q06418 1/20 0.39
AURKB Q96GD4 1/20 0.39
MAPK8 P45983 1/20 0.39
MAPK9 P45984 1/20 0.39
MAPK10 P53779 1/20 0.39
STAT6 P42226 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4403243 0.82 SYK (0.52) SYKSERPINE1JAK2JAK1JAK3
SCHEMBL5027838 0.81 MAPK9 (0.58) SYKJAK2JAK1JAK3TYK2
SCHEMBL2692644 0.80 SYK (0.52) SYKJAK2JAK1JAK3KCNH2
SCHEMBL894614 0.78 CSF1R (0.55) SYKJAK2JAK1JAK3TYK2
SCHEMBL2695855 0.78 SYK (0.55) SYKJAK2JAK1JAK3TYK2
SCHEMBL2696101 0.78 JAK3 (0.51) SYKJAK2JAK1JAK3TYK2
SCHEMBL2696747 0.78 JAK3 (0.51) SYKJAK2JAK1JAK3TYK2
SCHEMBL2182279 0.77 KCNH2 (0.48) SYKJAK2JAK1JAK3KCNH2
SCHEMBL4403249 0.77 TBK1 (0.40) SYKSERPINE1JAK2
SCHEMBL2696891 0.77 SYK (0.54) SYKJAK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2975027-A1 NICOTINAMIDES AS JAK KINASE MODULATORS Portola Pharmaceuticals, Inc. (US) 2016-01-20 EP disclosed
US-20150353495-A1 NICOTINAMIDES AS JAK KINASE MODULATORS ALEXION PHARMACEUTICALS, INC. 2015-12-10 US disclosed
US-20150353495-A1 NICOTINAMIDES AS JAK KINASE MODULATORS ALEXION PHARMACEUTICALS, INC. 2015-12-10 US disclosed
US-9102625-B2 Nicotinamides as JAK kinase modulators PORTOLA PHARMACEUTICALS, INC. (US) 2015-08-11 US disclosed
US-9102625-B2 Nicotinamides as JAK kinase modulators PORTOLA PHARMACEUTICALS, INC. (US) 2015-08-11 US disclosed
WO-2012061428-A2 NICOTINAMIDES AS JAK KINASE MODULATORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-05-10 WO disclosed
US-20120108566-A1 NICOTINAMIDES AS JAK KINASE MODULATORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108566-A1 NICOTINAMIDES AS JAK KINASE MODULATORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353495-A1 NICOTINAMIDES AS JAK KINASE MODULATORS JAK2, JAK1, NADK SYK 17/4885SERPINE1 996/4885JAK2 1/4885
US-20120108566-A1 NICOTINAMIDES AS JAK KINASE MODULATORS JAK2, JAK1, NADK SYK 17/4885SERPINE1 996/4885JAK2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.